All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Arzerra® (ofatumumab) given ‘positive opinion’ by the EMA CHMP for use in combination therapy in relapsed CLL
On the 10th November 2016, the EMA CHMP gave a positive opinion for a change to the terms of marketing authorization for Arzerra®, ofatumumab, which was submitted by Novartis Europharm Ltd1. The new positive opinion extends the use of ofatumumab to adult patients with relapsed CLL, when used in combination with fludarabine and cyclophosphamide.
The new opinion is based on the open-label, randomized, Phase III COMPLEMENT 2 study2 which evaluated the efficacy of using ofatumumab in combination with both fludarabine and cyclophosphamide, compared with the combination without ofatumumab. The COMPLEMENT 2 study presented data that the median PFS of the group who received ofatumumab in addition to fludarabine and cyclophosphamide was 28.9 months, compared with 18.8 months in the group who did not receive ofatumumab (HR =0.67, p=0.0032).
The full positive opinion for Arzerra® (ofatumumab) now reads:
"Previously untreated chronic lymphocytic leukaemia (CLL):
Arzerra® in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy.
Relapsed CLL:
Arzerra® is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL.
Refractory CLL:
Arzerra® is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab."
References
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?